CV 9202

Drug Profile

CV 9202

Alternative Names: BI 1361849; CV-9202

Latest Information Update: 02 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CureVac; Ludwig Institute for Cancer Research
  • Developer Boehringer Ingelheim; CureVac
  • Class Cancer vaccines; RNA vaccines
  • Mechanism of Action Immunostimulants; Toll-like receptor 7 modulators; Toll-like receptor 8 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-small cell lung cancer

Most Recent Events

  • 02 Jun 2017 Ludwig Institute for Cancer Research, Cancer Research Institute, Boehringer Ingelheim, MedImmune, CureVac and PharmaJet plan a phase I/II trial for Non-small cell lung cancer (Metastatic disease, Combination therapy, Second-line therapy or greater) in USA (NCT03164772)
  • 04 Aug 2016 CureVac AG terminates phase-I clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Austria, Germany and Switzerland (Intradermal) due to slow recruitment (NCT01915524)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Late-stage disease, Metastatic disease, Second-line therapy or greater) in Austria (Intradermal, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top